130 related articles for article (PubMed ID: 6152104)
1. The citalopram/5-HTP-induced head shake syndrome is correlated to 5-HT2 receptor affinity and also influenced by other transmitters.
Arnt J; Hyttel J; Larsen JJ
Acta Pharmacol Toxicol (Copenh); 1984 Nov; 55(5):363-72. PubMed ID: 6152104
[TBL] [Abstract][Full Text] [Related]
2. L-5-HTP facilitates the electrically stimulated flexor reflex in pithed rats: evidence for 5-HT2-receptor mediation.
Skarsfeldt T; Arnt J; Hyttel J
Eur J Pharmacol; 1990 Feb; 176(2):135-42. PubMed ID: 1968846
[TBL] [Abstract][Full Text] [Related]
3. Changes in rat dopamine- and serotonin function in vivo after prolonged administration of the specific 5-HT uptake inhibitor, citalopram.
Arnt J; Overø KF; Hyttel J; Olsen R
Psychopharmacology (Berl); 1984; 84(4):457-65. PubMed ID: 6441945
[TBL] [Abstract][Full Text] [Related]
4. Involvement of 5-HT2 receptors in the wet-dog shake behaviour induced by 5-hydroxytryptophan in the rat.
Yap CY; Taylor DA
Neuropharmacology; 1983 Jul; 22(7):801-4. PubMed ID: 6604883
[TBL] [Abstract][Full Text] [Related]
5. Prolonged treatment with the specific 5-HT-uptake inhibitor citalopram: effect on dopaminergic and serotonergic functions.
Arnt J; Hyttel J; Overø KF
Pol J Pharmacol Pharm; 1984; 36(2-3):221-30. PubMed ID: 6591152
[TBL] [Abstract][Full Text] [Related]
6. Correlations between different measures of antiserotonin activity of drugs. Study with neuroleptics and serotonin receptor blockers.
Ortmann R; Bischoff S; Radeke E; Buech O; Delini-Stula A
Naunyn Schmiedebergs Arch Pharmacol; 1982 Dec; 321(4):265-70. PubMed ID: 6132341
[TBL] [Abstract][Full Text] [Related]
7. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
Arnt J
Eur J Pharmacol; 1985 Jul; 113(1):79-88. PubMed ID: 2931283
[TBL] [Abstract][Full Text] [Related]
8. Effects of antidepressant drug combinations on cortical 5-HT2 receptors and wet-dog shakes in rats.
Koshikawa F; Koshikawa N; Stephenson JD
Eur J Pharmacol; 1985 Dec; 118(3):273-81. PubMed ID: 2935412
[TBL] [Abstract][Full Text] [Related]
9. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat.
Lucki I; Nobler MS; Frazer A
J Pharmacol Exp Ther; 1984 Jan; 228(1):133-9. PubMed ID: 6694097
[TBL] [Abstract][Full Text] [Related]
10. Further studies of the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats.
Arnt J; Hyttel J; Bach-Lauritsen T
Acta Pharmacol Toxicol (Copenh); 1986 Oct; 59(4):319-24. PubMed ID: 2879412
[TBL] [Abstract][Full Text] [Related]
11. Central antiserotonergic and antidopaminergic action of pirenperone, a putative 5-HT2 receptor antagonist.
Pawłowski L; Siwanowicz J; Bigajska K; Przegaliński E
Pol J Pharmacol Pharm; 1985; 37(2):179-96. PubMed ID: 4048012
[TBL] [Abstract][Full Text] [Related]
12. alpha2-Adrenoceptor antagonists reverse the 5-HT2 receptor antagonist suppression of head-twitch behavior in mice.
Matsumoto K; Mizowaki M; Thongpraditchote S; Murakami Y; Watanabe H
Pharmacol Biochem Behav; 1997 Mar; 56(3):417-22. PubMed ID: 9077577
[TBL] [Abstract][Full Text] [Related]
13. Interaction of the D1 receptor antagonist SCH 23390 with the central 5-HT system: radioligand binding studies, measurements of biochemical parameters and effects on L-5-HTP syndrome.
Bischoff S; Heinrich M; Krauss J; Sills MA; Williams M; Vassout A
J Recept Res; 1988; 8(1-4):107-20. PubMed ID: 3290470
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist.
Doble A; Girdlestone D; Piot O; Allam D; Betschart J; Boireau A; Dupuy A; Guérémy C; Ménager J; Zundel JL
Br J Pharmacol; 1992 Jan; 105(1):27-36. PubMed ID: 1596688
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological studies in vivo with ICI 169,369, a chemically novel 5-HT2/5-HT1C receptor antagonist.
Blackburn TP; Cox B; Thornber CW; Pearce RJ
Eur J Pharmacol; 1990 May; 180(2-3):229-37. PubMed ID: 2163866
[TBL] [Abstract][Full Text] [Related]
16. Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram.
Hyttel J; Overø KF; Arnt J
Psychopharmacology (Berl); 1984; 83(1):20-7. PubMed ID: 6429698
[TBL] [Abstract][Full Text] [Related]
17. DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'-oxoethyl)- piperidine HBr], a sigma and 5-hydroxytryptamine2 receptor antagonist: receptor-binding, electrophysiological and neuropharmacological profiles.
Tam SW; Steinfels GF; Gilligan PJ; Schmidt WK; Cook L
J Pharmacol Exp Ther; 1992 Dec; 263(3):1167-74. PubMed ID: 1361572
[TBL] [Abstract][Full Text] [Related]
18. Effect of the selective 5-HT3 receptor antagonists ICS 205-930 and MDL 72222 on 5-HTP-induced head shaking and behavioral symptoms induced by 5-methoxy-N,N,dimethyltryptamine in rats: comparison with some other 5-HT receptor antagonists.
Shearman GT; Tolcsvai L
Psychopharmacology (Berl); 1987; 92(4):520-3. PubMed ID: 3114804
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and serotonin 2 (5-HT2) receptor antagonist activity of 5-aminoalkyl-substituted pyrrolo[3,2-c]azepines and related compounds.
Mizuno A; Ogata A; Kamei T; Shibata M; Shimamoto T; Hayashi Y; Nakanishi K; Takiguchi C; Oka N; Inomata N
Chem Pharm Bull (Tokyo); 2000 May; 48(5):623-35. PubMed ID: 10823697
[TBL] [Abstract][Full Text] [Related]
20. Agonist and antagonist properties of serotonergic compounds in pigeons trained to discriminate either quipazine or L-5-hydroxytryptophan.
Yamamoto T; Walker EA; Woods JH
J Pharmacol Exp Ther; 1991 Sep; 258(3):999-1007. PubMed ID: 1890629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
